Acrux Limited · ASX:ACR
Acrux — Shareholder Meeting (November 2004)
10 slides from Acrux's shareholder meeting presentation, Nov 30, 2004
Slide 1: zg TN
zg TN , a niu oe oe i ; oe i Z ap Le y ee oo Le | L i Le y ey Le ae y 5 ie ee yy 7 ee : : Le ye Wy Te Z ial ; Ls oe ae Goes WITH PRODUCTS IN 2 TT i ue Ly Le xgOOOgOG ll NN ee a ccc nnn ae oa A he SST ee ye
Slide 2: Patient-preferred, patented technology for a range of valuable pharmaceuticals
i * Patient-preferred, patented technology for a range of valuable pharmaceuticals * Global commercial partnerships * Products in late stage development in large global markets ~ Two products in phase 3 clinical trials in USA by 2005 ~ Diversified product pipeline * Faster time to market with less r
Slide 3: Patchless Patch Technology Platform
AGRUX Patchless Patch® Reservoir TECHNOLOGY PLATFORM ot ACROSS eniancers Forms an invisible reservoir within the skin See Deliver need . ACROSS® Enhancers Allow drugs to pass through skin more rapidly MDTS® Applicator Used for simple, accurate & flexible dosing
Slide 4: No or low risk of skin irritation
2 a) No or low risk of skin irritation Cosmetic acceptability Dosage flexibility Ease of manufacture Cost effective Range of applications x) KIS KL KL KES KIN xX) xX) LK ANAS Preference by patients
Slide 5: Product pipeline by therapeutic area
een Therapeutic Area Menopausal Symptoms Femate Androgen insufficiency Market Size {Ussbn) Preclinical Testosterone MDTS' Severe Pain Fentanyl MDTS? Anxiety-Related Buspirone MOT: Maie Androgen Insufficiency Nausea Incontinence Contraception Smoking Cessation CNS Diseases Anti-Aging Skin Care Compan
Slide 6: VIVUS: NASDAQ listed company focused on sexual function disorders
VIVUS: NASDAQ listed company focused on sexual function disorders USS. licence for Estradiol MDTS® and Testosterone MDTS® Acrux retains rights for the rest of world (partnered with CSL for AU/NZ) VIVUS to initiate Phase 3 studies for Estradiol MDTS® by end 2004 and for Testosterone MDTS® in first ha
Slide 7: Partnerships and milestones achieved
cn ATG VIVUS Ine. CSL Lid. Development/Commercialisation deal for Commercialisation deal radiol & Female srone MDTS for Female Testosterone MDT Completed $30m IPO. and ASX Listing Awarded A$4. 2m ¢ i ompleted Phase | clinical Government grant inde al for Male Phase: 2b clinical tral trial for P? Pro
Slide 8: Upcoming development milestones
ON Estradiol Start Phase 3 Study H2 2004 H1 2005 Female Testosterone Finish Phase 2b Study 4 Start Phase 3 Study Fentanyl Finish Phase 1 Study Male Testosterone Finish Phase | Study 4 Nestorone Start Phase 1 Study M Veterinary Finish Clinical Study Granisetron Start Phase 1 Study Oxybutynin Start Ph
Slide 9: Licensing and R&D revenues
Licensing and R&D revenues 3.3 0.8 START grant - 1d Interest and other income 0.5 0.6 Total revenue 3.8 2 52% “Total expenditure (8.0) ~ &5% ~ “Net loss (42) _ 81% “Net cash outflow! (43) _ 830% 1 Includes: FY2004, Acquisition of patents ($0.4M) and Other cash flows $0.3M; FY2003, Premises refurbish
Slide 10: zg TN
zg TN , a niu oe oe i ; oe i Z ap Le y ee oo Le | L i Le y ey Le ae y 5 ie ee yy 7 ee : : Le ye Wy Te Z ial ; Ls oe ae Goes WITH PRODUCTS IN 2 TT i ue Ly Le xgOOOgOG ll NN ee a ccc nnn ae oa A he SST ee ye